Clinical Trial Details
| Trial ID: | L0065 |
| Source ID: | NCT03256526 |
| Associated Drug: | PF-06835919 |
| Title: | 6-week Safety and PD Study in Adults With NAFLD |
| Acronym: | -- |
| Status: | Completed |
| Study Results: | Has Results |
| Results: | https://ClinicalTrials.gov/show/NCT03256526/results |
| Conditions: | Non-alcoholic Fatty Liver Disease |
| Interventions: | Drug: Placebo|Drug: PF-06835919 Low Dose|Drug: PF-06835919 High Dose |
| Outcome Measures: | Percent Change From Baseline in Whole Liver Fat at Week 6|Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Post-dose Vital Signs Data Meeting Categorical Criteria|Number of Participants With Post-dose ECG Data Meeting Categorical Criteria|Number of Participants With Laboratory Abnormalities |
| Sponsor/Collaborators: | Pfizer |
| Gender: | All |
| Age: | 18 Years to 65 Years ?? (Adult, Older Adult) |
| Phases: | Phase 2 |
| Enrollment: | 53 |
| Study Type: | Interventional |
| Study Designs: | Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science |
| Start Date: | September 27, 2017 |
| Completion Date: | April 27, 2018 |
| Results First Posted: | April 4, 2019 |
| Last Update Posted: | April 4, 2019 |
| Locations: | National Research Institute, Los Angeles, California, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Stand-Up MRI of Miami, Miami, Florida, United States|Avail Clinical Research, LLC, Orange City, Florida, United States|Qps-Mra, Llc, South Miami, Florida, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|WR-ClinSearch LLC, Chattanooga, Tennessee, United States|Clinical Trials of Texas, Inc., San Antonio, Texas, United States|National Clinical Research, Inc, Richmond, Virginia, United States |
| URL: | https://ClinicalTrials.gov/show/NCT03256526 |
